First Financial Corp IN Has $1.25 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

First Financial Corp IN trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 1.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,292 shares of the medical research company’s stock after selling 34 shares during the period. Thermo Fisher Scientific comprises approximately 0.8% of First Financial Corp IN’s investment portfolio, making the stock its 19th biggest position. First Financial Corp IN’s holdings in Thermo Fisher Scientific were worth $1,246,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Norges Bank acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $2,784,029,000. BlackRock Inc. lifted its position in Thermo Fisher Scientific by 3.8% in the 4th quarter. BlackRock Inc. now owns 30,982,611 shares of the medical research company’s stock valued at $20,672,838,000 after acquiring an additional 1,143,333 shares in the last quarter. Parnassus Investments LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $552,948,000. Marshall Wace LLP lifted its position in shares of Thermo Fisher Scientific by 146.4% during the 4th quarter. Marshall Wace LLP now owns 1,043,844 shares of the medical research company’s stock worth $696,497,000 after buying an additional 620,291 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Thermo Fisher Scientific by 3.4% during the 4th quarter. State Street Corp now owns 16,223,173 shares of the medical research company’s stock worth $10,828,875,000 after buying an additional 529,712 shares in the last quarter. 86.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on TMO shares. SVB Leerink lifted their price objective on shares of Thermo Fisher Scientific from $630.00 to $650.00 and gave the company an “outperform” rating in a research note on Friday, July 29th. Credit Suisse Group began coverage on shares of Thermo Fisher Scientific in a report on Wednesday, August 24th. They set a “neutral” rating and a $675.00 price objective for the company. Barclays lowered their price target on shares of Thermo Fisher Scientific from $685.00 to $595.00 and set an “overweight” rating for the company in a research note on Monday, September 12th. Finally, Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $670.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday, July 29th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $656.56.

Insider Activity at Thermo Fisher Scientific

In other news, Director Jim P. Manzi sold 814 shares of the business’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $597.24, for a total value of $486,153.36. Following the completion of the sale, the director now owns 15,807 shares in the company, valued at approximately $9,440,572.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, SVP Michael A. Boxer sold 7,283 shares of the business’s stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $590.80, for a total transaction of $4,302,796.40. Following the completion of the transaction, the senior vice president now owns 12,398 shares in the company, valued at approximately $7,324,738.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jim P. Manzi sold 814 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $597.24, for a total transaction of $486,153.36. Following the transaction, the director now owns 15,807 shares of the company’s stock, valued at approximately $9,440,572.68. The disclosure for this sale can be found here. Insiders sold 55,397 shares of company stock worth $33,012,754 in the last 90 days. 0.43% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded down $1.18 on Friday, reaching $519.11. The company’s stock had a trading volume of 47,273 shares, compared to its average volume of 1,076,331. Thermo Fisher Scientific Inc. has a 52-week low of $497.83 and a 52-week high of $672.34. The company has a market cap of $203.38 billion, a P/E ratio of 27.46, a PEG ratio of 1.64 and a beta of 0.85. The company has a 50-day simple moving average of $567.60 and a 200 day simple moving average of $558.21. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.13 and a current ratio of 1.65.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last released its quarterly earnings results on Thursday, July 28th. The medical research company reported $5.51 EPS for the quarter, topping analysts’ consensus estimates of $4.92 by $0.59. Thermo Fisher Scientific had a net margin of 17.37% and a return on equity of 24.36%. The firm had revenue of $10.97 billion during the quarter, compared to analysts’ expectations of $9.95 billion. During the same period in the previous year, the company earned $5.60 EPS. The firm’s revenue for the quarter was up 18.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 22.92 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 14th. Investors of record on Thursday, September 15th will be issued a dividend of $0.30 per share. The ex-dividend date is Wednesday, September 14th. This represents a $1.20 dividend on an annualized basis and a yield of 0.23%. Thermo Fisher Scientific’s payout ratio is 6.39%.

Thermo Fisher Scientific Company Profile

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.